Global Nuclear Medicine/Radiopharmaceuticals Market
The global Nuclear Medicine/Radiopharmaceuticals market was valued at USD 4.63 billion in 2016 and is projected to reach USD 10.28 billion by 2025, growing at a CAGR of 9.27% from 2017 to 2025.
A Radiopharmaceutical is a drug that can be used either for diagnostic or therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells.
1. Market Drivers
1.1 Increasing Investment Through Public-Private Partnerships
1.2 Rising Alpha Radioimmunotherapy (Rit)-Based Targeted Cancer Treatment
1.3 Advances in Radiotracers
1.4 Increasing Incidence and Prevalence of Cancer and Cardiac Ailments
2. Market Restraints
2.1 Shorter Half-Life of Radiopharmaceuticals
2.2 High Cost
1. By Application:
1.1 Diagnostic Applications
1.1.1 SPECT Applications
1.2 Other SPECT Applications
1.2.1 PET Applications
18.104.22.168 Other PET Applications
1.2.2 Therapeutic Applications
1.2.4 Bone Metastasis
1.2.6 Endocrine Tumors
1.2.7 Other Therapeutic Applications
2. By Procedural Volume:
2.1 Diagnostic Procedures
2.1.1 SPECT Radiopharmaceuticals
2.1.2 PET Radiopharmaceuticals
2.2 Therapeutic Procedures
2.2.1 Beta Emitters
2.2.2 Alpha Emitters
2.2.3 Brachytherapy Isotopes
3. By Type:
3.1 Diagnostic Nuclear Medicine
3.1.1 SPECT Radiopharmaceuticals
22.214.171.124 Other SPECT Isotopes
3.2 PET Radiopharmaceuticals
3.2.3 Other PET Isotopes
3.3 Therapeutic Nuclear Medicine/ Radiopharmaceuticals
3.3.1 Beta Emitters
126.96.36.199 Other Beta Emitters
3.3.2 Alpha Emitters
3.3.3 Brachytherapy Isotopes
188.8.131.52 Other Brachytherapy Isotopes
4. By Region:
4.1 North America (U.S., Canada, Mexico)
4.2 Europe (Germany, UK, France, Rest of Europe)
4.3 Asia Pacific (China, India, Japan, Rest of Asia Pacific)
4.4 Latin America (Brazil, Argentina, Rest of Latin America)
4.5 Middle East & Africa
The major players in the market are as follows:
1. Cardinal Health, Inc.
2. Mallinckrodt PLC
3. GE Healthcare (A Fully-Owned Subsidiary of General Electric Company)
4. Lantheus Medical Imaging, Inc.
5. Bayer AG
6. Bracco Imaging S.P.A
7. Eczacibasi-Monrol Nuclear Products
8. Nordion, Inc. (A Subsidiary of Sterigenics International LLC.)
9. Advanced Accelerator Applications S.A.
10. Iba Molecular
These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market.
RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE:
Research study on the Nuclear Medicine/Radiopharmaceuticalsmarketwas performed in five phases which include Secondary research, Primary research, subject matter expert advice, quality check and final review.
The market data was analyzed and forecasted using market statistical and coherent models. Also market shares and key trends were taken into consideration while making the report. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis.
To know more about the Research Methodology of Verified Market Intelligence and other aspects of the research study, kindly get in touch with our sales team.
Verified Market Research has been providing Research Reports, with up to date information, and in-depth analysis, for several years now, to individuals and companies alike that are looking for accurate Research Data. It has large database which includes the latest content from renowned authors and publications worldwide. It also provides customized Data and Reports according to the need of the client.